Last reviewed · How we verify

Calaspargase pegol-mknl — Competitive Intelligence Brief

Calaspargase pegol-mknl (Calaspargase pegol-mknl) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Asparaginase (pegylated). Area: Oncology.

phase 3 Asparaginase (pegylated) Asparagine (amino acid depletion) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Calaspargase pegol-mknl (Calaspargase pegol-mknl) — M.D. Anderson Cancer Center. Calaspargase pegol-mknl is a pegylated asparaginase that depletes asparagine, an amino acid required for leukemic cell survival and proliferation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Calaspargase pegol-mknl TARGET Calaspargase pegol-mknl M.D. Anderson Cancer Center phase 3 Asparaginase (pegylated) Asparagine (amino acid depletion)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Asparaginase (pegylated) class)

  1. M.D. Anderson Cancer Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Calaspargase pegol-mknl — Competitive Intelligence Brief. https://druglandscape.com/ci/calaspargase-pegol-mknl. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: